LLY.SW stock opened pre-market down 7.69%, at CHF 720.00 on 24 Mar 2026 after a sharp re-rate on the SIX listing. We see short-term technical pressure and valuation concerns driving the move. Volume on the SIX snapshot is tiny at 2 shares, so price moves reflect cross-listing flows and sentiment more than local liquidity. We break down fundamentals, technicals, and Meyka AI forecasts to show possible support and targets for traders and investors.
LLY.SW stock: price action and immediate drivers
Eli Lilly and Company (LLY.SW) trades on SIX in CHF and opened at CHF 720.00, down CHF 60.00 from the previous close of CHF 780.00. The one-day move equals -7.69% and puts the stock below its 50-day average of CHF 806.60 but close to its 200-day average of CHF 718.48. Low SIX volume of 2 shares suggests the move reflects broader re-rating on the ADR and cross-market flows. We link recent headlines for context and monitor U.S. liquidity for confirmation MarketWatch LLY coverage.
Fundamentals and valuation for LLY.SW stock
Eli Lilly reports EPS 18.18 and a trailing PE of 39.60, above the Healthcare sector average PE of 29.67. Market capitalization on the SIX snapshot reads CHF 554.76B. Key ratios: price-to-sales 10.83, price-to-book 30.96, and dividend yield 0.68%. Strong margins and high ROE support the premium multiple, but the stock faces valuation sensitivity if growth expectations slip. We note research and development expense runs 21.47% of revenue, showing continued pipeline investment.
Technical picture and short-term risk for LLY.SW stock
Technicals show rapid deterioration: RSI 30.81, MACD histogram negative, and Bollinger lower band at CHF 702.11. The stock is oversold on CCI at -202.57, and Williams %R reads -100.00. On the SIX listing, the 200-day average is CHF 718.48, a near-term support level. Traders should watch CHF 700.00 as a psychological support and CHF 760.29 as the quarterly model resistance level.
Earnings calendar, catalysts and sector context for LLY.SW stock
Next reported earnings date is 30 Apr 2026. Catalyst risk includes clinical readouts and U.S. pricing headlines. The Healthcare sector has fallen -8.00% YTD, increasing sensitivity to profit-taking. Eli Lilly’s diversified portfolio, including diabetes and oncology drugs, reduces single-product risk, but any guidance change could trigger further re-rating. See portfolio effects in broader funds and holdings StockAnalysis holdings snapshot.
Meyka grade and model forecast for LLY.SW stock
Meyka AI rates LLY.SW with a score of 76.67 out of 100, Grade B+, suggestion: BUY. This grade factors in S&P 500 and sector comparisons, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a yearly price of CHF 974.73, a 35.37% implied upside from CHF 720.00. Forecasts are model-based projections and not guarantees. We include those figures to show a structured, data-driven base case for investors.
Price targets, scenarios and risk management for LLY.SW stock
We set three scenario targets: conservative CHF 760.29, base CHF 974.73, and bull CHF 1,272.79 based on Meyka AI outputs and technical levels. Downside case tests CHF 700.00 then CHF 540.00 (year low). Key risks: valuation re-rating, regulatory or pricing changes, and disappointing trial results. Use position sizing and stop-loss rules if trading the pre-market volatility.
Final Thoughts
LLY.SW stock is the top pre-market loser on 24 Mar 2026, trading at CHF 720.00 and down 7.69%. The move combines a short-term technical unwind with valuation sensitivity. Fundamentals remain strong: EPS 18.18, trailing PE 39.60, and robust free cash flow metrics. Meyka AI’s forecast model projects a yearly price of CHF 974.73, implying 35.37% upside versus today’s price. We rate this as a structured base case, not a guarantee. Given low SIX volume, traders should confirm direction on U.S. liquidity and watch CHF 700.00 support closely. For investors, consider staged entries around technical support and monitor upcoming earnings on 30 Apr 2026. Meyka AI-powered market analysis platform provides this model output as a tool for planning, not as financial advice.
FAQs
Why is LLY.SW stock falling pre-market today?
LLY.SW stock fell 7.69% pre-market on 24 Mar 2026 due to a rapid technical re-rate and valuation pressure. Low SIX volume suggests moves reflect cross-listed liquidity and broader sentiment rather than local news.
What are key valuation metrics for LLY.SW stock?
LLY.SW shows EPS 18.18, trailing PE 39.60, price-to-sales 10.83, and dividend yield 0.68%. These metrics place the stock above Healthcare peers and increase sensitivity to growth misses.
What price targets and forecast exist for LLY.SW stock?
Meyka AI’s model gives a conservative target CHF 760.29, base CHF 974.73, and bull CHF 1,272.79. The yearly forecast implies 35.37% upside from CHF 720.00; forecasts are model projections, not guarantees.
How should traders manage risk with LLY.SW stock now?
Manage risk with smaller position sizes and clear stops. Watch CHF 700.00 support and confirm moves on higher U.S. liquidity. Avoid adding into volatility without catalyst confirmation.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask our AI about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)